- Home
- REFR vs VERU Comparison
REFR vs VERU Comparison
Compare REFR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- VERU
- Stock Information
- Founded
- REFR 1965
- VERU 1971
- Country
- REFR United States
- VERU United States
- Employees
- REFR N/A
- VERU N/A
- Industry
- REFR Multi-Sector Companies
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- VERU Health Care
- Exchange
- REFR Nasdaq
- VERU Nasdaq
- Market Cap
- REFR 51.8M
- VERU 54.6M
- IPO Year
- REFR N/A
- VERU 1990
- Fundamental
- Price
- REFR $1.74
- VERU $4.29
- Analyst Decision
- REFR
- VERU Strong Buy
- Analyst Count
- REFR 0
- VERU 3
- Target Price
- REFR N/A
- VERU $33.33
- AVG Volume (30 Days)
- REFR 48.7K
- VERU 158.4K
- Earning Date
- REFR 11-06-2025
- VERU 08-12-2025
- Dividend Yield
- REFR N/A
- VERU N/A
- EPS Growth
- REFR N/A
- VERU N/A
- EPS
- REFR N/A
- VERU N/A
- Revenue
- REFR $1,222,239.00
- VERU $16,886,419.00
- Revenue This Year
- REFR N/A
- VERU N/A
- Revenue Next Year
- REFR N/A
- VERU N/A
- P/E Ratio
- REFR N/A
- VERU N/A
- Revenue Growth
- REFR N/A
- VERU 337.24
- 52 Week Low
- REFR $0.93
- VERU $2.64
- 52 Week High
- REFR $2.31
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- REFR 65.88
- VERU 74.55
- Support Level
- REFR $1.40
- VERU $3.75
- Resistance Level
- REFR $1.63
- VERU $3.99
- Average True Range (ATR)
- REFR 0.14
- VERU 0.24
- MACD
- REFR 0.02
- VERU -0.01
- Stochastic Oscillator
- REFR 96.51
- VERU 94.34
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.